30th International Workshop on Surfactant Replacement

Scientific Programme

Stockholm, Sweden | June 5th - 6th, 2015
Dear Colleagues and Friends,

It is a great honour for me to invite you all to the 30th International Workshop on Surfactant Replacement which will be held in Stockholm, Sweden, June 5th-6th, 2015.

This annual meeting has been held in different places in Europe but we now return to the place where the research about Curosurf started. The meeting in 2015 will be in Aula Medica at Karolinska Institutet, Stockholm, in the lecture hall where the Nobel Lectures in Physiology or Medicine are given.

The most important topics in neonatology including basic and clinical surfactant research will be discussed during the meeting.

Well-known invited speakers from all over of the world will cover different neonatal topics, but as always free papers and posters from the participants are very important to obtain a highly qualitative program.

I am looking forward to meeting you in Stockholm.

Kindest Regards,

SCIENTIFIC COMMITTEE
Tore Curstedt (Stockholm, Sweden)
Henry L. Halliday (Belfast, UK)
Mikko Hallman (Oulu, Finland)
Ola D. Saugstad (Oslo, Norway)
Christian P. Speer (Würzburg, Germany)

CHAIRPERSONS
Sture Andersson (Helsinki, Finland)
Mats Blennow (Stockholm, Sweden)
Kajsa Bohlin (Stockholm, Sweden)
Giuseppe Buonocore (Siena, Italy)
Vigilio P. Carnelli (Ancona, Italy)
Tore Curstedt (Stockholm, Sweden)
Henry L. Halliday (Belfast, UK)
Mikko Hallman (Oulu, Finland)
Jan Johansson (Stockholm, Sweden)
Boris Kramer (Maastricht, The Netherlands)
Eren Özek (Istanbul, Turkey)
Richard Plavka (Prague, Czech Republic)
Rangasamy Ramanathan (Los Angeles, USA)
Ola D. Saugstad (Oslo, Norway)
Kris Sekar (Oklahoma City, USA)
Eric Shinwell (Tel Aviv and Tsfat, Israel)
Christian P. Speer (Würzburg, Germany)
Ben Stenson (Edinburgh, UK)
Bo Sun (Shanghai, China)
David Sweet (Belfast, UK)
Maximo Vento (Valencia, Spain)
Luc Zimmermann (Maastricht, The Netherlands)

INVITED SPEAKERS
Christopher Baker (Denver, USA)
Dirk Baasler (Zürich, Switzerland)
Mats Blennow (Stockholm, Sweden)
Kajsa Bohlin (Stockholm, Sweden)
Tore Curstedt (Stockholm, Sweden)
Henry L. Halliday (Belfast, UK)
Mikko Hallman (Oulu, Finland)
Aaron Hamvas (Chicago, USA)
Dominique Haumont (Brüssel, Belgium)
Hugo Lagercrantz (Stockholm, Sweden)
Christian P. Speer (Würzburg, Germany)
Rangasamy Ramanathan (Los Angeles, USA)
Ola D. Saugstad (Oslo, Norway)
Eric Shinwell (Tsfat and Tel Aviv, Israel)
Bernard Thébaud (Ottawa, Canada)
Frank van Bel (Utrecht, The Netherlands)
Friday, June 5th

08.30 – 08.45  WELCOME ADDRESS
Anders Hamsten
Vice-Chancellor of Karolinska Institutet, Stockholm, Sweden
Tore Curstedt, Stockholm, Sweden

Chairpersons: Tore Curstedt (Stockholm, Sweden) Henry L. Halliday (Belfast, UK)

08.45 – 09.30  7th Bengt Robertson Memorial Lecture
ETHICS OF BIRTH AT THE LIMITS OF VIABILITY: THE RISKY BUSINESS OF PREDICTION
Eric Shinwell (Tel Aviv and Tsfat, Israel)
Chairpersons: Ola D. Saugstad (Oslo, Norway) Mikko Hallman (Oulu, Finland)

09.30 – 10.20  Invited Lecture
A UNIQUE STORY IN NEONATAL RESEARCH: THE DEVELOPMENT OF A PORCINE SURFACTANT
Tore Curstedt, (Stockholm, Sweden), Henry L. Halliday (Belfast, UK), Christian P. Speer (Warzburg, Germany)

10.20 – 10.50 Coffee Break
Chairpersons: Rangasamy Ramanathan (Los Angeles, USA) Virgilio Carnielli (Ancona, Italy)

10.50 – 11.10 Invited Lecture
SURFACTANT AND NON-INVASIVE VENTILATION
Mats Blennow (Stockholm, Sweden)

Oral Presentations

11.10 – 11.20 LESS INVASIVE SURFACTANT ADMINISTRATION (LISA) IS SAFE: TWO YEAR FOLLOW-UP OF 476 INFANTS
E.H. Herling, A. Kirbs, B. Roth, C. Hartel, W. Gose and members of the German Neonatal Network (GNN) (Cologne and Luebeck, Germany)

11.20 – 11.30 ATOMISED SURFACTANT IMPROVES OXYGENATION AND HOMOGENEITY OF VENTILATION IN SPONTANEOUSLY BREATHING PRETERM LAMBS RECEIVING: CPAP

11.30 – 11.40 SUPRAGLOTTIC ATOMIZATION OF CUROSURF® VIA A NEW DELIVERY SYSTEM ALLOWS HIGH LUNG DEPOSITION
A. Nord, R. Linne, I. Milesi, E. Zanin, D. Dellaca, F. Bianco, M. Di Castri, D. Cunha: Goncalves, V. Perez-de-Sa (Lund, Sweden and Milan and Parma, Italy)

11.40 – 11.50 NEBULIZATION OF PORACTANT ALFA VIA A VIBRATING MEMBRANE NEBULIZER IN SPONTANEOUSLY BREATHING PRETERM LAMBS WITH BINASAL CONTINUOUS POSITIVE PRESSURE VENTILATION

11.50 – 12.05 Discussion

12.05 – 13.05 Lunch and Poster Viewing

13.05 – 14.25 Poster Presentations 1
Chairpersons: David Sweet (Belfast, UK) Sture Andersson (Helsinki, Finland)

Poster 1 RETROSPECTIVE ANALYSIS OF SURFACTANT ADMINISTRATION IN PRETERM INFANTS IN NON INVASIVE RESPIRATORY SUPPORT: LISA VS INSURE PROCEDURE
F. Castoldi, P. Fontana, S. Martinei, L. Bardi, A. C. Marucco, P. Basrenta, E. Lupo, S. Gatto, G. Lista (Milan, Italy)

Poster 2 COMPARISON OF THE SURFACTANT ADMINISTRATION VIA THIN CATHETER DURING SPONTANEOUS BREATHING WITH THE INSURE PROCEDURE IN PRETERM INFANTS
N. Akoçay, A.S. Gokalp, A. Gunlnez, F. Kiliç, E. A. Arisoy, G. Turker (Kocaeli, Turkey)

Poster 3 NASAL CPAP VERSUS BI-LEVEL CPAP FOR EARLY RESCUE TREATMENT OF RESPIRATORY DISTRESS SYNDROME IN PRETERM INFANTS: PRELIMINARY REPORT
Poster 4
SURFACANT TREATMENT COMPARED TO NASAL CONTINUOUS POSITIVE AIRWAY PRESSURE FOR THE MANAGEMENT OF RESPIRATORY DISTRESS SYNDROME IN THE NEWBORN BETWEEN 35 AND 41 WEEKS OF GESTATION (THE ASPEN STUDY)

Poster 5
EFFECTS OF SYNCHRONIZED INTERMITTENT MANDATORY VENTILATION VS PRESSURE SUPPORT PLUS VOLUME GUARANTEE VENTILATION IN THE WEANING PHASE OF PRETERM INFANTS
Aydin Erdemir, Zelal Kahramaner, Ebru Turkoğlu, Hese Cosar, Sumer Sutcuoglu, Esra Arun Özer (Izmir, Turkey)

Poster 6
VOLUME GUARANTEE ON HIGH FREQUENCY OSCILLATORY VENTILATION IN PRETERM INFANTS: IS IT NEW LUNG PROTECTIVE STRATEGY
B. Iscan, N. Duman, F. Tuzun, A. Kumral, H. Özkan (Izmir, Turkey)

Poster 7
EFFECT OF EXTERNAL INSPIRATORY LOADING ON DIAPHRAGMATIC FUNCTION OF PRETERM AND TERM INFANTS
G. Dimitriou, S. Fouzas, A. Vervenioti, P. Pelekouda (Patras, Greece)

Poster 8
EFFECTS OF BOLUS SURFACANT THERAPY ON SERIAL PERIPHERAL PERFUSION INDEX AND TISSUE CARBON MONOXIDE MEASUREMENTS IN PRETERM INFANTS WITH SEVERE RESPIRATORY DISTRESS SYNDROME
D. Terek, D. Gönülal, O. Koroglu, M. Yalaz, M. Akisu, N. Kultursay (Izmir, Turkey)

Poster 9
PROTECTIVE EFFECTS OF VALPROIC ACID VIA SEVERAL MECHANISMS AGAINST HYPEROXIC LUNG INJURY IN A NEONATAL RAT MODEL

Poster 10
LUNG LAVAGE WITH DILUTE SURFACANT VERSUS BOLUS SURFACANT FOR MECONIUM ASPIRATION SYNDROME: A RANDOMISED CONTROLLED TRIAL

Poster 11
ANTENATAL STEROIDS AND PULMONARY OUTCOME IN NEONATES WITH A GESTATIONAL AGE < 32 WEEKS
E. Gulczyńska, M. K. Borszewska-Kornacka, M. Kostuch, I. Sadowska-Krawczenko, P. Korbal and the Polish study group (Łódź, Poland)

Poster 12
NOVEL BIOMARKERS FOR THE ASSESSMENT OF INTRAAMNIOTIC INFECTION
V. Stefanovic, A. Sánchez-Illana, J. Kuligowski, S. Andersson, J. Escobar, I. Torres-Cuevas, A. Nuñez, E. Cabells, M. Cernada, M. Vento, C. Chafer-Pericas (Helsinki, Finland and Valencia, Spain)

Poster 13
EVALUATION OF LUNG FUNCTION IN PRESCHOOL CHILDREN BORN LATE-PRETERM WITH IMPULSE OSCILLOMETRY
I. Er, A. Gunlemez, Z. S. Uyan, M. Aydogan, O. Isik, M. Oruc, A. E. Arisoy, G. Turker, A. S. Gokalp (Izmir, Turkey)

Poster 14
THE EFFECT OF CLARITHROMYCIN PROPHYLAXIS ON DEVELOPMENT OF BRONCHOPULMONARY DYSPLASIA IN PRETERM INFANTS

Poster 15
DIAGNOSTIC ACCURACY OF LUNG ULTRASOUND IN THE CRASHING INFANT: AN INTERNATIONAL, PROSPECTIVE STUDY
F. Migliaro, J. R. Fanjul, S. Aversa, N. Youssef, I. Corsini, L. Grappone, A. Sodano, F. Raimondi on behalf of the LUCI investigators (Naples, Italy)

Poster 16
EFFECT OF RECOMBINANT HUMAN ERYTHROPOIETIN ON TRACHEAL ASPIRATE INFLAMMATORY MARKERS IN VENTILATED PRETERM NEONATES
K. Saraﬁdis, A. Thomaidou, V. Soubasi, A. Taparkou, E. Diamant, V. Drosou (Thessaloniki, Greece)

Poster 17
THE EFFECTS OF MATERNAL ANTICOAGULANT THERAPY ON CORD BLOOD ANGIOGENIC FACTORS AND NEONATAL RESPIRATORY MORBIDITY IN WOMEN WITH RECURRENT MISCARRIAGE
S. Taki, S. Yigit, A. Korkmaz, M. Yurdakok (Ankara, Turkey)

Chairpersons: Eren Özek (Istanbul, Turkey) & Kris Sekar (Oklahoma City, USA)
30th International Workshop on Surfactant Replacement
Stockholm, Sweden | June 5th - 6th, 2015

Chairpersons: Giuseppe Buonocore (Siena, Italy) Luc Zimmermann (Maastricht, The Netherlands)

14.30 – 15.10
Invited Lecture
LUNGS, MICROBES AND THE DEVELOPING NEONATE
Aaron Hamvas (Chicago, USA)

15.10 – 15.25
Oral Presentations
MIXTURES OF CUROSURF AND POLYMXYXIN E AND POLYMXYXIN B ARE REDUCING PULMONARY AND SYSTEMIC BACTERIAL LOAD IN NEONATAL RABBIT PNEUMONIA
G. Stichtenoth, M. Hägerstrand-Björkman, B. Linderholm, E. Herting, T. Curstedt (Stockholm, Sweden and Lübeck, Germany)

15.25 – 15.40
CAN SURFACTANT PREPARATIONS BE USED AS DRUG CARRIER?
O. Basabe-Burgos, M. Hägerstrand-Björkman, B. Linderholm, K. Nordling, G. Stichtenoth, P. Bergman, T. Curstedt, J. Johansson, A. Rising (Stockholm, Sweden and Lübeck, Germany)

15.40 – 15.55
EFFECTS OF THE NEW GENERATION SYNTHETIC SURFACTANT CHF5633 ON PRO- AND ANTI-INFLAMMATORY CYTOKINE RESPONSES IN CD4+ MONOCYTES AND CD4+ LYMPHOCYTES
K. Glaser, M. Fehrholz, T. Curstedt, S. Kunzmann, S. Seidenspinner, C. P. Speer (Würzburg, Germany and Stockholm, Sweden)

15.55 – 16.25
Coffee Break

Chairpersons: Richard Plavka (Prague, Czech Republic) Bo Sun (Shanghai, China)

16.25 – 17.05
Invited Lecture
IMPAIRED PULMONARY VASCULAR DEVELOPMENT IN BRONCHOPULMONARY DYSPLASIA
Christopher Baker (Denver, USA)

17.05 – 17.20
Oral Presentations
EARLY INTRAVENOUS PARACETAMOL AND PDA CLOSURE IN VERY PRETERM INFANTS: A RANDOMIZED, CONTROLLED TRIAL
P. Harkin, A. Harma, O. Aikio, M. Valkama, M. Leskinen, T. Saarela, M. Hallman (Oulu, Finland)

17.20 – 17.35
PHYSICAL ACTIVITY AND THE RISK OF PRETERM BIRTH: A SYSTEMATIC REVIEW AND META-ANALYSIS OF EPIDEMIOLOGICAL STUDIES
D. Aune, T. Henriksen, O.D. Saugstad, S. Tonstad, L.J. Vatten (Oslo and Trondheim, Norway)
Saturday, June 6th

Chairpersons: Christian P. Speer (Würzburg, Germany) Ben Stenson (Edinburgh, UK)

Invited Lecture
08.30 – 09.00
ANTENATAL STEROID BEFORE PRETERM BIRTH
Mikko Hallman (Oulu, Finland)

Invited Lecture
09.00 – 09.25
INHALATION OR INSTILLATION OF STEROIDS FOR THE PREVENTION OF BRONCHOPULMONARY DYSPLASIA
Dirk Bassler (Zürich, Switzerland)

Oral Presentations
09.25 – 09.40
OPPOSITE EFFECTS OF PROGESTERONE AND DEXAMETHASONE (DEX) ON SURFACTANT-PROTEIN B (SP-B) PRODUCTION
S. Kunzmann, M. Fehrholz, B. W. Kramer, C. P. Speer (Würzburg, Germany and Maastricht, The Netherlands)

09.40 – 09.55
DEXPANTHENOL THERAPY REDUCES LUNG DAMAGE IN A HYPEROXIC LUNG INJURY IN NEONATAL RATS

09.55 – 10.10
A BPD-MODEL IN NEWBORN MICE
C. Revhaug, M Zasada, A.G. Rogndien, A. Madekzo-Talowska, M. Bik-Multanowski, P. Kwintt, P Pietrzyk, O.D. Saugstad (Krakow, Poland/Oslo, Norway)

10.10 – 10.40 Coffee Break

Chairpersons: Jan Johansson (Stockholm, Sweden) Boris Kramer (Maastricht, The Netherlands)

Invited Lecture
10.40 – 11.20
STEM CELLS FOR PREVENTION OF NEONATAL LUNG DISEASES
Bernard Thébaud (Ottawa, Canada)

Oral Presentations
11.20 – 11.35
MESenchymal STEM- OR STROMAL CELLS (MSCS) FROM THE DEVELOPING HUMAN LUNG
M.A. Mohtas, S. Koss, D. Freund, R.K. Ohls, M. Rüdiger, B. Thébaud (Dresden, Germany and Ottawa, Canada)

11.35 – 11.50
SAFETY ASPECTS OF INTRAVENOUS MESENCHYMAL STEM CELL TRANSPLANTATION IN PRETERM INFANTS
E. Henckel, G. Goetherstrom, K. Le Blanc, B. Hallberg, K. Bohlin (Stockholm, Sweden)

Chairpersons: Kajsa Bohlin (Stockholm, Sweden) Max Vento (Valencia, Spain)

Invited Lecture
11.50 – 12.20
DELIVERY ROOM HANDLING OF TERM AND PRETERM NEWLY BORN INFANTS
Ola D. Saugstad (Oslo, Norway)

Oral Presentations
12.20 – 12.35
CHANGING PATTERNS OF SURFACTANT USE OVER TWO DECADES FOR BABIES <30 WEEKS GESTATION IN NORTHERN IRELAND’S REGIONAL INTENSIVE CARE UNIT
J.C.A Courtney, B. McNaughton, D. G. Sweet (Belfast, UK)

12.35 – 12.50
RELEVANCE OF URINARY LIPID PEROXIDATION BYPRODUCTS IN PRETERM INFANTS FOR PREDICTING NEONATAL CONDITIONS
J. Kuligowski, M. Aguar, D. Rook, I. Lliso, I. Torres-Cuevas, J. Escobar, G. Quintás, M. Brugada, A. Sánchez-Illana, J. B. van Goudoever, M. Vento (Valencia, Spain and Rotterdam and Amsterdam, The Netherlands)

12.50 – 14.30 Lunch
Post Conference Workshop

Chairpersons: Mats Blennow (Stockholm, Sweden) Eric Shinwell (Tel Aviv and Tsfat, Israel)

14.30 – 15.00  ONSET OF BREATHING AND EMERGENCE OF THE MIND AT BIRTH  
Hugo Lagercrantz (Stockholm, Sweden)

15.00 – 15.30  NEUROMONITORING THE HIGH RISK PRETERM INFANTS. ITS CLINICAL RELEVANCE?  
Frank van Bel (Utrecht, The Netherlands)

15.30 – 15.50  Coffee Break

15.50 – 16.20  USE OF IT TO MONITOR NOSOCOMIAL INFECTIONS AND PREVENTIVE STRATEGIES  
Dominique Haumont (Bruxelles, Belgium)

16.20 – 16.50  FAMILY CENTRED CARE  
Kajsa Bohlin (Stockholm, Sweden)

16.30 – 17.00  CLOSING REMARKS AND INVITATION TO NAPLES  
Tore Curstedt (Stockholm, Sweden) / Giuseppe Buonocore (Siena, Italy)
**Poster 1**

**RETROSPECTIVE ANALYSIS OF SURFACTANT ADMINISTRATION IN PRETERM INFANTS IN NON INVASIVE RESPIRATORY SUPPORT: LISA VS INSURE PROCEDURE**

Francesca Castoldi; Paola Fontana; Stefano Martinelli; Laura Iardi; Annamaria Cirillo Maruesso; Petrina Bastrenta; Enrica Luppi; Sara Gatto; Gianluca Lista

NICU, V.Buzzi Children’s Hospital ICP, Milan, Italy

**BACKGROUND**

Surfactant instillation via INtubation-SURfactant-Extubation (INSURE) method requires intubation; manual or mechanical ventilation (MV) can induce lung injury. Recently, a less invasive surfactant administration (LISA) method via a thin catheter inserted in trachea in spontaneously breathing infants in non invasive ventilation (NIV) has been developed. The aim of this study is to report clinical and respiratory outcomes of preterm neonates in NIV for Respiratory Distress Syndrome (RDS) after administration of Surfactant through LISA compared to INSURE procedure.

**PATIENT AND METHODS**

A retrospective study conducted in 2 NICUs (V.Buzzi and Niguarda Hospital, Milan, Italy) from 2/2012 to 10/2014; charts of infants undergoing NIV for RDS who required surfactant administration (200 mg/kg, Curosurf®) for FiO2 >35% were reviewed; the choice of INSURE or LISA was left to the neonatologist on duty; LISA was administered through a thin tracheal aspiration catheter or a umbilical catheter, depending on the center of birth. Clinical characteristics, respiratory outcomes as days of NIV, number of surfactant doses, need for MV within 72 hours, days of O2 support, were analyzed in the 2 groups. The two centers followed the same criteria for intubation and MV, and for discontinuation of MV and extubation. Statistical analysis of clinical data was performed by Fisher exact test, Chi-squared test and t-Student’s test.

**RESULTS**

58 infants received INSURE and 28 infants LISA; clinical characteristics of infants (INSURE vs LISA BW 1341±478g vs 1308±584g; GA 29±2 vs 29±2 wks respectively) and antenatal steroids therapy (46/58 vs 25/28) were similar. No adverse events occurred during surfactant administration. No differences were observed in NIV failure, length of MV and oxygen support, PNX, IVH, significant PDA, BPD and death occurrence. No differences were observed between the two centers. Infants who failed CPAP and needed MV in LISA group had lower BW vs INSURE group (845±179 g vs 1186±465g respectively; p=ns).

**CONCLUSIONS**

In our study no differences in short and long term outcomes were observed between administration of surfactant via INSURE or LISA method to preterm infants in NIV for RDS.

**Poster 2**

**COMPARISON OF THE SURFACTANT ADMINISTRATION VIA THIN CATHETER DURING SPONTANEOUS BREATHING WITH THE INSURE PROCEDURE IN PRETERM INFANTS**

N. Akçay; A.S. Gokalp; A. Gunlemез; F. Kılıçbay; A.E. Arsoy; G. Turker

Department of Pediatrics, Division of Neonatology, University of Kocaeli, Turkey

**BACKGROUND**

The aim of this prospective study is to investigate the effectiveness of a technique of minimally invasive surfactant therapy (MIST) in preterm infants on continuous positive airway pressure (CPAP) and comparison of the results with the InSurE.

**PATIENT AND METHODS**

78 preterm infants less than 32 weeks of gestational age need surfactant therapy were enrolled in this study. Infants who need resuscitation in the delivery room, major congenital anomalies, hidrops fetalis were excluded from the study. Preterm infants, who were less than 32 weeks and stabilized with nasal continuous positive airway pressure (nCPAP) in the delivery room, were randomized to receive early surfactant treatment either by via thin catheter (MIST) or InSurE technique. Tracheal instillation of 100 mg/kg poractant a via 5-F catheter during spontaneous breathing under nCPAP was performed in the MIST group (n 42). In the InSurE technique procedure, 36 infants were intubated, received positive pressure ventilation for 30 seconds after surfactant instillation, and placed on nCPAP immediately.

**RESULTS**

There were no difference between the demographic data, needs of resuscitation in the delivery room and the Apgar scores of the MIST and InSurE group. Need for intubation within the first 72 hours, readministration of surfactant, duration of nCPAP, incidence of pneumothorax, pulmonary hemorrhage, early sepsis, PDA, NEC, IVH, BPD and mortality were similar in both groups and there were no statistically significant difference between them (Table). Blood pCO2 values were not different in both groups before surfactant administration, whereas after treatment MIST group had significantly lower.

**CONCLUSIONS**

MIST technique has been found as effective as InSurE technique. The surfactant administration in preterm infants the InSurE method should be preferred because it is noninvasive and easy to apply.
Poster 3

NASAL CPAP VERSUS BI-LEVEL CPAP FOR EARLY RESCUE TREATMENT OF RESPIRATORY DISTRESS SYNDROME IN PRETERM INFANTS: PRELIMINARY REPORT
Sema Arayici, Gulsum Kadioglu Simsek, Evrim Alyamac Dizdar, Birgun Say, Mehmet Yekta Oncel, Fatma Nur Sari, Nurdan Uras, Serife Suna Oguz, Fuat Emre Canpolat, Ugur Dilmen
Neonatology, Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey

BACKGROUND
To compare the effectiveness of nasal continuous positive airway pressure (nCPAP) with variable flow and bi-level nasal CPAP (BiPAP) as primary mode of treatment for RDS in preterm infants.

PATIENT AND METHODS
In this prospective randomized study, preterm infants lower than 32 weeks of gestational age and 1500 gr who were admitted to the neonatal intensive care unit were screened for eligibility following parental consent. Enrolled infants were randomized into two study groups; nCPAP and BiPAP group. Non-invasive respiratory support was delivered using the infant flow-driver device (Viasys Corp, Care Fusion, CA). Surfactant therapy requirement was evaluated in all preterm infants after admission. Poractant alfa was administered using a non-invasive technique if necessary. Infants in both groups were compared with regard to failure of non-invasive respiratory support. Short and long-term neonatal outcomes were also evaluated.

RESULTS
A total of 52 patients were enrolled for the study. There was no significant difference between the nCPAP and BiPAP groups in terms of demographic characteristics. Statistically significant difference was observed between groups with regard to failure of non-invasive respiratory support (35% vs 8.3%; p=0.024). More patients in the nCPAP group required surfactant therapy compared to the BiPAP group (60.7% vs 16.7%; p=0.002). Four patients (14.3%) in the nCPAP group and 1 patient (4.2%) in the BiPAP group (p=0.33) required oxygen on day 28.

CONCLUSIONS
Preliminary results showed that fewer infants required mechanical ventilation and surfactant therapy in the BiPAP group compared to the nCPAP group. Neonatal outcomes will be more clearly defined after completion of the study.
SURFACTANT TREATMENT COMPARED TO NASAL CONTINUOUS POSITIVE AIRWAY PRESSURE FOR THE MANAGEMENT OF RESPIRATORY DISTRESS SYNDROME IN THE NEWBORN BETWEEN 35 AND 41 WEEKS OF GESTATION (THE ASPEN STUDY)

Pierre Tourneux; Thierry Blanc; Bernard Guillou; Serge Klosowski; Julien Mourdie; Caroline Lardennois; Hocine Boumecid; Valérie Datin Dorriere; Guy Kongolo; Ghida Ramadan-Ghostine; Cécile Fontaine; François Morea
Neonatal intensive care unit, CHU Amiens, PeriTox UMI01 INERIS, Faculté de Médecine, UPJV, France

BACKGROUND
Term and near-term newborns can present with acute respiratory distress syndrome (RDS). Surfactant treatment has been shown to be effective in reducing the duration of mechanical ventilation and oxygen treatment in preterm newborns. Whether surfactant treatment is also beneficial in term and near-term newborns is unknown. The purpose of this randomized trial was to compare surfactant treatment with nasal continuous positive airway pressure (nCPAP) in term and near-term newborns with RDS within the first 24 hours of life.

PATIENT AND METHODS
Newborns born between 35 and 41 weeks of gestation, with RDS within the first 24 hours of life treated with nCPAP and with an FiO2 ≥ 30% but < 60% at enrolment were eligible. Newborns with nCPAP and an FiO2 > 60%, polynamalformative syndrome, heart disease, shock, blood gas pH 65 mmHg, or perinatal asphyxia were excluded. Newborns were randomly assigned to two groups: “surfactant treatment after tracheal intubation” (Surfactant group) and “continuation of nCPAP” (nCPAP group). Rescue surfactant treatment was used in the second group if FiO2 reached > 60%. In each group, newborns were weaned from mechanical ventilation and oxygen treatment as soon as possible.

The primary outcome of the study was the success of the procedure, defined as “survival without oxygen treatment” at 72 hours of life.

RESULTS
Nineteen newborns were included: 10 in the nCPAP group and 9 in the Surfactant group. The study was stopped because of the low incidence of RDS in eligible newborns. There was no significant difference between the two groups in terms of gestational age (36.1±2.23 gestational weeks in nCPAP vs. 36.1±2.03 gestational weeks in the Surfactant group), birth weight or Apgar score. The probability of “survival without oxygen treatment” at 72 hours of life was 50±18% in the Surfactant group vs. 20±13% in the nCPAP group (p=0.19). Five newborns (50%) in the nCPAP group required rescue surfactant treatment. Two newborns in the nCPAP group developed pneumothorax, compared to none in the Surfactant group (p = 0.47).

CONCLUSIONS
We did not observe any significant difference between surfactant treatment vs. nCPAP in newborns between 35 and 41 weeks of gestation with RDS within the first 24 hours of life, probably due to the lack of power of the study. Five newborns (50%) in the nCPAP group required rescue surfactant treatment. The interest of using less invasive surfactant administration (LISA) in newborns with RDS treated with nCPAP and an FiO2 > 30% should be studied.
RESTROSPECTIVE ANALYSIS OF SURFACTANT ADMINISTRATION IN PRETERM EFFECTS OF SYNCHRONISED INTERMITTENT MANDATORY VENTILATION VS. PRESSURE SUPPORT PLUS VOLUME GUARANTEE VENTILATION IN THE WEANING PHASE OF PRETERM INFANTS

Aydin Erdemir; Zelal Kahramaner; Ebru Turkoglu; Hese Cosar; Sumer Sutcuoglu; Esra Arun Ozer
Izmir Tıpeçik Education and Research Hospital, Neonatology Clinic, Yenisehir, Izmir, Turkey

BACKGROUND
The aim of this study is to compare the effects and short-term outcomes of pressure support ventilation with volume guarantee (PSV+VG) vs. synchronized intermittent mandatory ventilation (SIMV) in the weaning phase of very low birth weight infants with respiratory distress syndrome (RDS).

PATIENT AND METHODS
A total of 60 premature infants who were <33 weeks gestation and/or <1500 gram birth weight and received mechanical ventilation because of respiratory distress syndrome were included in this randomized, controlled, prospective study. All infants were ventilated from the time of admission with synchronized intermittent positive pressure ventilation (SIPPV) mode after surfactant treatment for RDS and then switched to PSV+VG or SIMV mode in the weaning phase. The ventilatory parameters and neonatal outcomes were recorded in each groups.

RESULTS
The mean peak inflation pressure (PIP) was higher in SIMV group (p<0.001) and the mean airway pressure (MAP) was higher in PSV+VG group (p=0.03) whereas mean tidal volume and respiratory rates were similar in both groups. The incidence of post-extubation atelectasis was higher in SIMV group but the difference was not statistically significant (p=0.08). No differences were found in the incidence of re-intubation, patent ductus arteriosus, intraventricular hemorrhage, retinopathy of prematurity, bronchopulmonary dysplasia and pneumothorax between the groups.

CONCLUSIONS
PSV+VG mode may be a safe and feasible mode during the weaning phase of very low birth weight infants on mechanical ventilation support for RDS in respect to reducing the frequency of post-extubation atelectasis and using less PIP.

VOLUME GUARANTEE ON HIGH FREQUENCY OSCILLATORY VENTILATION IN PRTERM INFANTS: IS IT NEW LUNG PROTECTIVE STRATEGY

Burcin Iscan; Nuray Dumanc; Funda Turun; Abdullah Kumral; Hasan Orkan
Department of Pediatrics, Division of Neonatology, Dokuz Eylul University, School of Medicine, Izmir, Turkey

BACKGROUND
High frequency oscillatory ventilation (HFOV) theoretically limits baro/volutrauma using subdeadspacce volumes but lack of direct control over tidal volume resulting in fluctuating PCO₂ level. Volume guarantee plus high-frequency oscillatory ventilation (HFOV+VG) is a new ventilation mode allows the clinician to set a mean tidal volume to be delivered. This study aimed to investigate the feasibility and efficacy of this mode of ventilation in premature infants with respiratory distress syndrome (RDS).

PATIENT AND METHODS
Inborn infants at less than 32 weeks of gestation with respiratory distress syndrome (RDS) were enrolled in the study if they required invasive mechanical ventilation. Patients were randomized to receive either HFOV plus VG or HFOV as the initial ventilator mode and then crossed over to the other mode of ventilation. HFOV was performed with “optimal lung volume strategy” during both study period.

RESULTS
During the study period twenty-four infants ventilated for RDS were included in the study. There was no significant difference between ventilation mode in terms of mean amplitude and mean airway pressure (Paw) but high frequency tidal volume (VThf), minute ventilation (MVe) and carbon dioxide diffusion coefficient (DCO2) values were significantly higher in the HFOV+VG mode and hypocarbia and hypercarbia frequency was found to be less in HFOVs+VG periods.

CONCLUSIONS
This is the first prospective, randomized, crossover clinical study that compared HFOV with and without VG in infants with acute RDS. In this study, when used HFOV combined with VG demonstrated that equal airway pressure provides better ventilation and can achieve optimal gas exchange. HFOV combined with VG may be an effective and feasible for preterm infants.
Poster 7

**EFFECT OF EXTERNAL INSPIRATORY LOADING ON DIAPHRAGMATIC FUNCTION OF PRETERM AND TERM INFANTS**

G. Dimitriou; S. Fouzas; A. Vervenioti; P. Pelekouda
Neonatal Intensive Care Unit, Department of Paediatrics, School of Medicine, University of Patras, Greece

**BACKGROUND**

Newborns, especially those born prematurely, may present limited ability to adapt to additional respiratory loads, i.e. during acute respiratory disease or upper airway obstruction. The diaphragmatic pressure-time product (PTPdi) reflects the energy expenditure of the diaphragm and has been used as a measure of the work of breathing. The diaphragmatic pressure-time index (PTIdi) describes the pressure-generating activity of the diaphragm and assesses the balance between the capacity of the diaphragm and the load imposed upon it. In adults, a PTIdi greater than 0.15-0.18 may indicate impending diaphragmatic fatigue.

The aim of this study is to compare the changes in diaphragmatic function after application of inspiratory flow-resistive loading in preterm and term infants.

**PATIENT AND METHODS**

Sixteen preterm infants (median GA 32.5 weeks, range 30–34) and 16 term infants (median GA 38 weeks, range 37–40) were studied prior to discharge from the NICU. None of the preterm infants had chronic lung disease and all infants were breathing on room air when studied. PTPdi was calculated as the integral of transdiaphragmatic pressure over time. PTIdi was calculated as the product of the mean to the maximum transdiaphragmatic pressure ratio (Pdimean/Pdimax) and the inspiratory duty cycle (Ti/Ttot). The mean PTPdi and PTIdi were computed before and during application of an inspiratory flow resistance of 200 cmH2O for 120 seconds.

**RESULTS**

Resistive loading resulted in significantly higher increase of PTPdi and PTIdi in infants born preterm (PTPdi median [range] 58 [32-138]% vs. 35 [24-51]%, P<0.001 and PTIdi 67 [31-142]% vs. 35 [16-42]%, P<0.001, respectively). PTPdi and PTIdi became significantly higher in preterm infants after application of inspiratory resistance (0.102 [0.068-0.189] vs. 0.076 [0.044-0.119], P<0.001). Three preterm infants (18.8%) had post-resistance PTIdi higher than the reported adult fatigability threshold of 0.15. Multivariable linear regression analysis revealed that PTPdi and PTIdi increase after logarithmic transformation were inversely related to GA (P=0.001 and P=0.040, respectively), independently of gender, birthweight, days of mechanical ventilation and postconceptional age at the time of measurement.

**CONCLUSIONS**

Under conditions that increase the inspiratory load, prematurity is associated with increased work of breathing and higher risk of diaphragmatic muscle fatigue.

---

Poster 8

**EFFECTS OF BOLUS SURFACANT THERAPY ON SERIAL PERIPHERAL PERFUSION INDEX AND TISSUE CARBON MONOXIDE MEASUREMENTS IN PRETERM INFANTS WITH SEVERE RESPIRATORY DISTRESS SYNDROME**

D. Terek, D. Gönülal, O. Altun Koroglu, M. Yalaz, M. Akisu, N. Kultursay
Division of Neonatology, Department of Pediatrics, Ege University Faculty of Medicine, Izmir, Turkey

**BACKGROUND**

Exogenous bolus surfactant administration may affect hemodynamic parameters and peripheral perfusion. We aimed to investigate the effects of surfactant on perfusion index (PI) and transcutaneous carbon monoxide (TCO), hemodynamic and ventilatory parameters.

**PATIENT AND METHODS**

PI and TCO values were measured before and 0, 5, 30, 60 and 360 minutes after surfactant administration in the first six hours of life in preterm infants with respiratory distress syndrome (RDS) treated with poractantalfa or beractant and preterm infants without RDS. Thirty preterm infants with RDS treated with poractantalfa (n=15) or beractant (n=15) and 18 preterm infants without RDS were enrolled to study.

**RESULTS**

Study group had lower Tp PI and higher Tp TCO levels than controls. Both preparations improved mean arterial pressure, oxygenation index, pH and lactate levels. Median Tp PI value of 1.3 decreased to 0.86 at T0 (P < 0.001), and then increased to 0.99 at T5 (P < 0.001) and to 1.25 at T30 (P = 0.037). Median Tp TCO value of 3 decreased to 2, 1.5, 0 and 0 at T0, T5, T30, T60 respectively (P < 0.001). PI more quickly improved (30 versus 60 minutes) and reached control group values (30 versus 360 minutes) with beractant compared to poractantalfa. TCO improved similarly in both groups (5 versus 5 min).

**CONCLUSIONS**

Peripheral perfusion improved with both preparations only after a decline in the first minute. TCO declined continuously and reached control group showing pulmonary function improvement or anti-inflammatory effect of surfactant. Noninvasive surfactant administration may prevent initial negative effect of bolus treatment on peripheral perfusion lasting for at least one minute.
**Poster 9**

**PROTECTIVE EFFECTS OF VALPROIC ACID VIA SEVERAL MECHANISMS AGAINST HYPEROXIC LUNG INJURY IN A NEONATAL RAT MODEL**

Merih Cetinkaya; Mehmet Cansev; Caneyt Tayman; Fuat Emre Canpolat; Ilker Mustafa Kafa; Eura Orenlik Yaylagul; Boris W. Kramer; Serdar Umit Sarici

*Kanuni Sultan Süleyman Training and Research Hospital, Istanbul, Turkey*

**BACKGROUND**

Histone acetylation and deacetylation may play a role in the pathogenesis of inflammatory lung diseases. We evaluated the preventive effect of valproic acid (VPA); a histone deacetylase (HDAC) inhibitor; on neonatal hyperoxic lung injury.

**PATIENT AND METHODS**

Forty newborn rat pups were randomized in normoxia; normoxia+VPA; hyperoxia and hyperoxia+VPA groups. Pups in the normoxia and normoxia+VPA groups were kept in room air and received daily saline and VPA (30 mg/kg) injections; respectively; while those in hyperoxia and hyperoxia+VPA groups were exposed to 95% O2 and received daily saline and VPA (30 mg/kg) injections for 10 days; respectively. Growth; histopathological; biochemical and molecular biological indicators of lung injury; apoptosis; inflammation; fibrosis and histone acetylation were evaluated.

**RESULTS**

VPA treatment during hyperoxia significantly improved weight gain; histopathologic grade; radial alveolar count and lamellar body membrane protein expression; while it decreased number of TUNEL(+)-cells and active Caspase-3 expression. Expressions of TGFβ3 and phospho-SMAD2 proteins and levels of tissue proinflammatory cytokines as well as lipid peroxidation biomarkers were reduced; while anti-oxidative enzyme activities were enhanced by VPA treatment. VPA administration also reduced HDAC activity while increasing acetylated H3 and H4 protein expressions.

**CONCLUSIONS**

The present study shows for the first time that VPA treatment ameliorates lung damage in a neonatal rat model of hyperoxic lung injury. The preventive effect of VPA involves HDAC inhibition.

---

**Poster 10**

**LUNG LAVAGE WITH DILUTE SURFACTANT VERSUS BOLUS SURFACTANT FOR MECONIUM ASPIRATION SYNDROME: A RANDOMISED CONTROLLED TRIAL**

Sema Arayici; Fatma Nur Sari; Gulsum Kadioglu Simsek; Erbu Yarci; Evrim Alyamac Dizdar; Nurdan Uras; Serife Suna Ogun; Fuat Emre Canpolat; Ugur Dilmen

*Neonatology; Zekai Tahir Burak Maternity Teaching Hospital; Ankara; Turkey*

**BACKGROUND**

To compare the effect of lung lavage with dilute porcine surfactant and bolus surfactant administration in the treatment of infants with meconium aspiration syndrome (MAS).

**PATIENT AND METHODS**

In this prospective randomized controlled study; ventilated infants with MAS with a gestational age ≥ 36; birth weight ≥ 2000 g were included. Infants were randomized into two groups; in group 1; two sequential 15 mL/kg aliquots of dilute porcine surfactant (Curosurf; Chiesi Farmaceutici S.p.A.; Parma; Italy) with a phospholipid concentration of 5 mg/ml were instilled into the lung. In group 2; 100 mg/kg of porcine surfactant were administered as a bolus. The study groups were compared with regard to efficacy; morbidity and mortality.

**RESULTS**

Thirty-three infants were randomized. Median duration of mechanical respiratory support was similar in infants who underwent lung lavage and bolus surfactant (3 versus 3.5 days; p=0.36). Similarly; duration of oxygen therapy and hospitalization were not significantly different between the groups (5 versus 7 days; p=0.48; 12.5 versus 12 days p=0.88; respectively). There were no differences in high frequency ventilation and nitric oxide requirement between the groups. Mortality and pneumothorax also did not differ between the groups.

**CONCLUSIONS**

Lung lavage with dilute surfactant therapy does not alter the neonatal outcomes in terms of the duration of respiratory support; need of high frequency ventilation and nitric oxide; mortality and duration of hospitalization in ventilated infants with MAS.
ANTENATAL STEROIDS AND PULMONARY OUTCOME IN NEONATES WITH A GESTATIONAL AGE ≤ 32 WEEKS
Ewa Guzkynska; Maria Katarzyna Borzewska-Kornacka; Marzena Kostuch; Iwona Krawczak-Sawczanko; Piotr Korbal and the Polish study group
Neonatal Department Polish Mother's Memorial Hospital Research Institute, Łódź, Poland

BACKGROUND
Antenatal corticosteroids are routinely used to promote lung maturity in premature neonates. The first Polish retrospective study aimed to evaluate the rate of antenatal use of corticosteroids and their effect on the incidence and treatment of respiratory disorders and survival rate.

PATIENT AND METHODS
Data of 987 neonates at gestational age of ≤ 32 weeks; treated at 54 centers; including tertiary (42) and secondary (12) referral centers; for the period of 6 months (between January 1, 2013 and June 30, 2013) were analyzed. The characteristics of both groups were similar according to: GA; BBW and gender.

RESULTS
The percentage of glucocorticosteroids used in secondary and tertiary referral centers in Poland was only 76% (749 vs 238). We confirmed the effectiveness of antenatal corticosteroids on: lower fraction of inspired oxygen used for delivery room stabilization of preterm (FiO2 0.4 i 0.5; p=0.0005); reduced rate of surfactant treatment (69.9% vs. 78.1%; p=0.0143; RR=0.8952 [95%CI 0.8247 to 0.9716]); reduced rate of mechanical ventilation 55.7% vs 70.6%; p=0.0001; RR=0.7887 [95%CI 0.7108 to 0.8752] shorter duration of mechanical ventilation (5.7 ±1.4 days vs 7.9 ±12.7 days; p=0.0001); improved survival rate until 36 weeks of corrected gestational age (10.8% vs. 20.9%; p=0.0001; RR=0.5172 [95%CI 0.3695 - 0.7239]). We also observed trends toward reduced rate of BPD @36 CA; 13.2% vs 18.6%; p <0.09.

CONCLUSIONS
The percentage of glucocorticosteroids used in secondary and tertiary referral centers in Poland is still unsatisfactorily low (76%). We confirmed high efficacy of antenatal corticosteroid on reduced rate of surfactant therapy, duration of mechanical ventilation and mortality rates.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Antenatal corticosteroids (N=749)</th>
<th>Controls (N=238)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birth weight; g; mean (5th; 95th percentile)</td>
<td>1216 (600; 1980)</td>
<td>1209 (520; 2021)</td>
<td>0.6463</td>
</tr>
<tr>
<td>GA; wk; mean (5th; 95th percentile)</td>
<td>28.7 (24; 32)</td>
<td>28.3 (23; 32)</td>
<td>0.3191</td>
</tr>
<tr>
<td>Sex; male; N(%)</td>
<td>390 (52;0)</td>
<td>124 (52;1)</td>
<td>0.9933</td>
</tr>
<tr>
<td>Outborn; N (%)</td>
<td>38 (5.0)</td>
<td>54 (22.7)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Apgar at 1 min; median (IQR)</td>
<td>6 (4-7)</td>
<td>5 (2-6)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Apgar at 5 min; median (IQR)</td>
<td>7 (6-8)</td>
<td>7 (6-8)</td>
<td>0.0084</td>
</tr>
<tr>
<td>Maximal FiO2 at DR; mean (5th; 95th percentile)</td>
<td>0.49 (0.25; 1)</td>
<td>0.59 (0.29; 1)</td>
<td>0.0005</td>
</tr>
<tr>
<td>Chest X-ray – degree of changes; median (IQR)</td>
<td>2(2-3)</td>
<td>2(2-3)</td>
<td>0.1205</td>
</tr>
<tr>
<td>Surfactant treatment; N(%)</td>
<td>524 (69.9)</td>
<td>186 (78.1)</td>
<td>0.0143</td>
</tr>
</tbody>
</table>
**NOVEL BIOMARKERS FOR THE ASSESSMENT OF INTRAAMNIOTIC INFECTION**

V. Stefanovic 1; A. Sánchez-Illana 2; J. Kuligowski 3; S. Andersson 4; J. Escobar 5; I. Torres-Cuevas 5; A. Nuñez 6; E. Cabells 5; M. Cernada 1; M. Vento 5,6; C. Chafer-Pericas 6

1 Department of Obstetrics and Gynecology; 2 Fetomaternal Medical Center, Helsinki University Hospital; 3 Neonatal Research Centre; 4 Health Research Institute La Fe, Valencia, Spain; 5 Division of Neonatology University & Polytechnic Hospital La Fe, Valencia, Spain

**BACKGROUND**

Intraamniotic infection/inflammation (IAI) and subsequent chorioamnionitis is a relevant factor triggering preterm birth; and is associated with adverse outcome (bronchopulmonary dysplasia; necrotizing enterocolitis; and brain white matter injury). However, there are limited data on oxidative stress and inflammation to the fetus after exposure to IAI. In sheep models; protein carbonyls were increased in plasma and airways; and myeloperoxidase in airways. Chorioamnionitis diagnosis is based on histological findings and/or clinical criteria. However; the histologic results do not always confirm the clinical diagnosis. In this concern; important efforts have been carried out to modify obstetric diagnosis of chorioamnionitis and intervene in cases of silent IAI before clinical chorioamnionitis occurs. Therefore; it is relevant to find new biomarkers that allow prompt diagnosis and optimize the timing of delivery.

**OBJECTIVE**

The aim of this work was to determine which biomarkers of oxidative stress; nitrosative stress; and inflammation could be used as early IAI biomarkers in amniotic fluid (AF) samples.

**METHODS**

35 AF samples collected from women grouped into three categories (normal; mild chorioamnionitis and intense chorioamnionitis) were analyzed following clinical and histological criteria. The analytical methods employed consisted of liquid chromatography coupled to mass spectrometry (LC-MS/MS). The analytes determined were tyrosines (3-NO2-tyr; 3-Chloro-tyr; o-tyr; p-tyr; m-tyr; phenylalanine); glutathione (GSH); glutathione sulfonamide (GSA); 8-hydroxy-2’-deoxyguanosine (8OH-dG) and 2’-deoxyguanosine (2-dG).

**RESULTS**

GSH; 8OH-dG and 2-dG concentrations in AF were not relevant biomarkers for revealing the presence of chorioamnionitis. However; the concentrations of inflammation biomarkers; such as; GSA; 3-NO2-tyr and 3-Chloro-tyr showed significant differences among the three categories studied (Table). GSA and 3-NO2-tyr concentration in AF correlated well with the chorioamnionitis diagnosis; but did not discriminate upon severity of chorioamnionitis. Remarkably; 3-Chloro-tyr concentration was significantly increased in severe chorioamnionitis; but did not between mild chorio and normal AF samples. Table. Comparison of biomarkers of oxidative stress & inflammation in amniotic fluid in patients with normal; mild or severe chorioamnionitis.

**CONCLUSIONS**

We conclude that AF GSA and 3-NO2-tyr can be useful as early biomarkers of the presence of IAI; moreover; 3-Chloro-tyr can be used to detect the presence of severe chorioamnionitis necessitating urgent delivery.
EVALUATION OF LUNG FUNCTION IN PRESCHOOL CHILDREN BORN LATE-PRETERM WITH IMPULSE OSCILLOMETRY
ER Ilkay; Md; Ayla Gunlemez; Zeynep Seda Uyan; Metin Aydogan; Olcay Isik; Meral Oruc; Ayse Engin Arisoy; Gulcan Turker; Ayse Sevim Gokalp
Neonatology Unit Department of Pediatrics; Kocaeli University, Kocaeli, Turkey

BACKGROUND
There is a paucity of data on lung physiology in late-preterm who may be exposed to a risk of decline in lung functions during childhood. In this study, we aimed to evaluate the lung function in preschool children born late-preterm using impulse oscillometry (IOS) and to compare the results with those obtained in healthy term-born children.

PATIENT AND METHODS
Children between 3 and 7 years of age born late-preterm who are currently being followed-up at the outpatient clinic were included as the late-preterm group. Age matched healthy term-born children served as controls. A total of 90 late-preterm and 75 healthy children were included in the study. 15 of late-preterm (7%) had received surfactant postnatally. At 5-20 Hz; resistances (R5-R20); reactances (X5-X20) and resonant frequency were measured by IOS.

RESULTS
The mean values of R5; R10 and Z5 were statistically higher in late-preterms who had been hospitalized for pulmonary infections as compared to controls (p<0.05). The mean R5; R10; R15; R20 and Z5 were significantly higher and the mean X10 and X15 were significantly lower in late-preterms with passive smoking compared to late-preterms without passive smoking and controls (p<0.05).

CONCLUSION
Children born late-preterm exhibited signs of peripheral airway obstruction as evidenced by the results of our IOS-based comparison with healthy term-born controls. Besides the inherent disadvantages of premature birth; hospitalization for pulmonary infection and passive smoking also seemed to adversely impact the lung functions in children born late-preterm.

Table I. Patient characteristics of the late-preterm group

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Late Preterm n=90</th>
<th>Controls n=75</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean gestational week (weeks)</td>
<td>35.27±0.90</td>
<td>37.04±0.85</td>
</tr>
<tr>
<td>Mean birth weight (g)</td>
<td>2429.62±514.71</td>
<td>2850.58±450.24</td>
</tr>
<tr>
<td>Male; n(%)</td>
<td>57(63.3%)</td>
<td>48(64%)</td>
</tr>
<tr>
<td>Cesarean section; n(%)</td>
<td>75(83.3%)</td>
<td>64(85.3%)</td>
</tr>
<tr>
<td>Mean APGAR score at 5 min</td>
<td>9.32±0.72</td>
<td>8.8±0.71</td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory disorder; n(%)</td>
<td>54(60)</td>
<td>48(64)</td>
</tr>
<tr>
<td>Non-respiratory disorder; n(%)</td>
<td>36(40)</td>
<td>27(36)</td>
</tr>
<tr>
<td>Respiratory support; n(%)</td>
<td>37(41.1)</td>
<td>25(33.3)</td>
</tr>
<tr>
<td>Surfactant treatment; n(%)</td>
<td>13(14.4)</td>
<td>9(12%)</td>
</tr>
<tr>
<td>Mean duration of hospitalization (days)</td>
<td>6.64±5.13</td>
<td>3.93±4.12</td>
</tr>
<tr>
<td>Maternal asthma during pregnancy; n(%)</td>
<td>5(5.6)</td>
<td>2(2.6)</td>
</tr>
<tr>
<td>Passive smoking; n(%)</td>
<td>53(58.9)</td>
<td>48(64)</td>
</tr>
<tr>
<td>Hospitalization for pulmonary infection; n(%)</td>
<td>27(30)</td>
<td>25(33.3)</td>
</tr>
</tbody>
</table>

Table II. IOS results for late-preterm group and controls

<table>
<thead>
<tr>
<th>IOS</th>
<th>Late-preterms (n=90)</th>
<th>Controls (n=75)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
</tr>
<tr>
<td>R5kPa/(L/s)</td>
<td>0.96</td>
<td>0.29</td>
<td>0.88</td>
</tr>
<tr>
<td>R10kPa/(L/s)</td>
<td>0.82</td>
<td>0.20</td>
<td>0.75</td>
</tr>
<tr>
<td>R15kPa/(L/s)</td>
<td>0.76</td>
<td>0.18</td>
<td>0.72</td>
</tr>
<tr>
<td>R20kPa/(L/s)</td>
<td>0.70</td>
<td>0.17</td>
<td>0.67</td>
</tr>
<tr>
<td>X5kPa/(L/s)</td>
<td>-0.27</td>
<td>0.11</td>
<td>-0.26</td>
</tr>
<tr>
<td>X10kPa/(L/s)</td>
<td>-0.15</td>
<td>0.09</td>
<td>-0.12</td>
</tr>
<tr>
<td>X15kPa/(L/s)</td>
<td>-0.09</td>
<td>0.08</td>
<td>-0.07</td>
</tr>
<tr>
<td>X20kPa/(L/s)</td>
<td>-0.00</td>
<td>0.08</td>
<td>0.01</td>
</tr>
<tr>
<td>Resfreq 1/s</td>
<td>19.57</td>
<td>3.72</td>
<td>18.52</td>
</tr>
<tr>
<td>Z5kPa/(L/s)</td>
<td>1.00</td>
<td>0.28</td>
<td>0.91</td>
</tr>
</tbody>
</table>
Ureaplasma urealyticum and Mycoplasma Hominis colonisation provided decreased moderate and severe BPD rate in preterm infants with/without were reached in preterm infants treated with clarithromycin. We speculated that; clarithromycin activity in preterm lung. Clarithromycin prophylaxis associated with diminished BPD rate in preterm infants colonisation with Ureaplasma urealyticum. We aimed to evaluate the efficacy of clarithromycin prophylaxis in preventing BPD in preterm infants with or without Ureaplasma urealyticum and Mycoplasma Hominis.

RESULTS

Infants who were eligible for the study were determined as preterms with a birth week and weight under 30 week and 1250 gram respectively. In the first 24 hours of infants; we randomised and separate two groups after the take culture for Ureaplasma Urealyticum and Mycoplasma Hominis. First group treated with clarithromycin during 10 days. Second group treated with saline as same as clarithromycin volume during 10 days. The outcomes for this study were the composite mortalities and others comorbidities such as bronchopulmonary dysplasia; intracranial bleeding; patent ductus arteriosus; necrotizing enterocolitis and retinopathy of prematurity. Exclusion criteria consisted of the presence of major congenital abnormalities; lack of parental informed consent; intrauterine growth retardation with a birth weight at the 10th percentile for gestational age and death in first 28 days of life.

METHODS

Infants and their parents provided written informed consent. Intrauterine growth retardation was determined when birth weight was below the 10th centile for gestational age. The study was approved by the local Ethics Committee (14 December 2011).

RESULTS

After the remove some patients because of exclusion criterias and death; 184 infants (92 each group) were analysed. There was no significant difference between the clarithromycin and placebo groups in terms of demographic characteristics. Mean gestational ages (27.4±1.3 vs. 27.4±1.5 weeks) and birth weights (1009±154 vs. 992±170 g) were similar. At least 28 days oxygen requirement rate were high in placebo group at 36 weeks PMA but statistically insignificant (51.1% vs. 41.3%; p=0.183). Moderate and severe BPD rate was significantly low in clarithromycin group compared with placebo group (28.3% vs. 8.7%; p=0.01). Otherwise; Ureaplasma and Mycoplasma colonisation rate was not different between clarithromycin and placebo groups.

CONCLUSIONS

Our result showed that; clarithromycin prophylaxis was not changed total BPD rate (mild; moderate and severe) in the study. At the same time; diminished moderate and severe BPD rate were reached in preterm infants treated with clarithromycine. We speculated that; clarithromycin prophylaxis provided decreased moderate and severe BPD rate in preterm infants with/without Ureaplasma urealyticum and Mycoplasma Hominis colonisation.
Poster 16

**EFFECT OF RECOMBINANT HUMAN ERYTHROPOIETIN ON TRACHEAL ASPIRATE INFLAMMATORY MARKERS IN VENTILATED PRETERM NEONATES**

Serafida Kosmas; Thomaidou Agathi; Soubasi Vasiliki; Taparkou Anna; Diamanti Elisavet; Drosou Vasiliki
1st Department of Neonatology of Aristotle University of Thessaloniki; “Hippokrateion” General Hospital; Thessaloniki; Greece

**BACKGROUND**
Existing evidence suggests a cytoprotective effect of erythropoietin (EPO) on various organs as a consequence of its multiple biological actions. OBJECTIVE: To test the hypothesis that recombinant human EPO (rhEPO) would ameliorate lung inflammation in ventilated preterm neonates.

**PATIENT AND METHODS**
Preterm neonates (gestational age ≤ 30 weeks) with respiratory failure requiring mechanical ventilation on day of life 1 (T1) were eligible for this prospective pilot study. Enrolled neonates were randomly assigned to receive either rhEPO (1500 IU/kg s.c X 3 per day at T1 followed by 250 IU/kg s.c X 3 per week [EPO group]) or placebo (control group). Tracheal aspirate (TA) samples were collected at T1 as well as on days of life 4-5 (T2) and 7-10 (T3) if still intubated. Serum EPO was also measured at the above time points. TA samples were analyzed for EPO; interleukins-6; 8 and 18; macrophage inflammatory protein-1 alpha; and monocyte chemotactic protein 1. White blood cell count and differential as well neutrophil respiratory burst activity (RBA) were measured (Flow cytometry) on TA samples.

**RESULTS**
Six and eight neonates comprised the EPO and control group; respectively. Serum and TA EPO levels were significantly increased at T2 in the EPO as compared to the control group. A significant correlation between serum and TA EPO levels was found at T1 and T2. However; TA levels of the cytokines studied as well as cell counts; differential and neutrophil RBA were comparable between groups.

**CONCLUSIONS**
Our results do not support an amelioration of lung inflammation in ventilated preterm neonates with the rhEPO doses given in this study. However; a possible favorable effect with higher EPO doses cannot be excluded.

Poster 17

**THE EFFECTS OF MATERNAL ANTICOAGULANT THERAPY ON CORD BLOOD ANGIOGENIC FACTORS AND NEONATAL RESPIRATORY MORBIDITY IN WOMEN WITH RECURRENT MISCARRIAGE**

S Takci; S Yigit; A Korkmaz; M Yurdakok
Hacettepe University Ihsan Dogramaci Children’s Hospital Ankara Turkey

**BACKGROUND**
Angiogenic imbalance of the placenta is one of the prominent pathophysiologic mechanism underlying pregnancy complications like recurrent miscarriage. Low molecular weight heparin and low dose aspirin are frequently used in the management of recurrent miscarriage. These treatments; mainly heparin has been shown to organize angiogenesis. Vascular endothelial growth factor (VEGF) and its soluble receptor-sFlt-1 plays a major role in angiogenesis which has an impact on respiratory problems of newborns. The first aim of this study is to investigate whether maternal use of LMWH and low dose aspirin combination therapy can alter the circulatory profile of VEGF-A and sFlt-1 in cord blood of infants; and the second aim is to determine any association between respiratory morbidity of the newborn and maternal anticoagulant usage.

**PATIENT AND METHODS**
Term newborns whose mothers were treated with LMWH and low dose aspirin due to recurrent miscarriage were prospectively included. A control group consisted of healthy gestational age matched infants without an adverse perinatal outcome who were born in the same period. The concentrations of VEGF-A and sFlt-1 in umbilical cord blood were assayed by ELISA and compared between study and control group. Short term neonatal outcomes and respiratory problems were also noted in two groups.

**RESULTS**
Forty four infants with a maternal LMWH and low dose aspirin usage during pregnancy and 42 healthy infants as a control group were included in the study. Serum VEGF-A level was detected in all samples (n=86) whereas 23 samples were above the detection limit for sFLT-1. There were no significant differences between the demographics; serum VEGF-A and sFlt-1 levels. There were also no correlation between the cumulative LMWH dosage and serum levels of these angiogenic factors. Respiratory problems (transient tachypnea of the newborn and pulmonary maladaptation) were more common in the study group compared to control group (10/44 versus 2/42; p<0.05).

**CONCLUSIONS**
LMWH and low dose aspirin treatment in mothers with recurrent miscarriage did not alter the circulatory profile of cord blood VEGF-A and sFlt-1 levels. These findings will contribute to improve our understanding the complex interactions of maternal anticoagulant therapy and angiogenic factors on fetal site. On the other hand the high frequency of respiratory problems in infants with maternal anticoagulant usage needs further evaluation.
Poster 18

EARLY IMMUNOMODULATORY EFFECTS OF DIFFERENT NATURAL SURFACTANT PREPARATIONS IN PRETERM INFANTS WITH RESPIRATORY DISTRESS SYNDROME
M. Yalaz; S. Tanriverdi; O. Uygur; O. Altun Koroglu; E. Azarsiz; G. Aksu; N. Kultursay
Division of Neonatology; Department of Pediatrics; Ege University Faculty of Medicine; Izmir; Turkey

BACKGROUND
Natural surfactant preparations are widely used for the treatment of respiratory distress syndrome (RDS). These preparations have either bovine or porcine surfactant proteins which may have immunoregulatory effects in the newborn lung. So far, little is known about the immunomodulatory effects of therapeutic surfactants. The aim of this study was to evaluate cytokine and chemokine response following three different regimens of natural surfactant treatment in preterm newborns with RDS.

PATIENT AND METHODS
Forty five preterm newborns (gestational age ≤32wk) with RDS requiring intubation in the first hours of life were randomized into 3 study groups: Group 1= Beractant; 100mg/kg; Group 2=Poractant alfa; 100mg/kg; Group 3= Poractant alfa; 200mg/kg. Blood and tracheal aspirate samples were obtained prior to surfactant treatment. The same sampling procedures were repeated 6 hours after surfactant. Eosinophil count of the blood and tracheal aspirate (TA) samples were performed by Abbott Cell DYN 3700 counter. Commercially available enzyme-linked immunosorbent assay (ELISA) kits were used to determine TNFα (inducible T Cell alpha chemoattractant); MIP3b (macrophage inflammatory protein 3 beta); IL-5; IL-8; IL-9; IL-10; IL-13; IgE; IFN-gamma; TGFbeta1 levels in blood and TA samples. Antenatal and clinical variables of the study groups were recorded prospectively.

RESULTS
Mean ±SD gestational age and birth weight of the study groups 1,2 and 3 were similar; 28.13 ±2.53 vs. 28.80±2.36 vs. 27.46±3.64 weeks and 1212±382.82 vs. 1319±390.952 vs. 1127±879±390.952 grams; respectively. Antenatal and clinical characteristics were also similar. No adverse effects related to surfactant treatment was observed in any study patients. TA samples: IFN-gamma concentration and eosinophil counts decreased after surfactant replacement in all groups, especially in the poractant-alfa treated infants. Eotaxin; TGF beta and IL-8 concentrations increased significantly in poractant-alfa treated infants. TA IL-9 levels decreased in the beractant group but increased in the poractant alfa groups. Blood samples: Blood levels of cytokines and chemokines showed significantly decreased levels of ITAC and MIP3b only in the beractant group; but were not informative for poractant alfa groups.

CONCLUSIONS
Natural surfactants have different immunomodulatory effects in the newborn lungs. This initial response was more pronounced in the poractant alfa groups.
Poster 20

EFFECTS OF PERINATAL STEROID THERAPY ON DEVELOPING BRAIN AND GROWTH FACTORS: WHAT IS THE CRITICAL TIME WINDOW?
Burcin Iscan 1; Abdullah Kumral 1; Funda Tuzun 1; Serap Cilaker Micib 2; Kazmi Tugyan 2; Nuray Duman 1; Hasan Orkan 1
1 Department of Pediatrics; Division of Neonatology; Dokuz Eylul University; School of Medicine; Izmir; Turkey
2 Department of Histology; Dokuz Eylul University; School of Medicine; Izmir; Turkey

BACKGROUND
Growth factors play an important role in the development of the central nervous system (CNS). Evidences suggest that glucocorticoid exposure at certain developmental stages have considerable effects on the development of the central nervous system (CNS). This study thus aimed to evaluate the differential effects of glucocorticoid exposure on critical growth factor levels during different stages of brain maturation.

PATIENT AND METHODS
Forty-two rat pups were divided into six groups according to the timing of betamethasone administration. Rats in the treatment groups were exposed to intraperitoneal betamethasone injection beginning at different time points (postnatal days 1; 2; and 3). Rats in the placebo group received the same volume of 0.9% saline via the same fashion. Pups were sacrificed at 24 hours after the last injection for neuronal density and immunohistochemical evaluation of Brain derived neurotrophic factor (BDNF); Transforming growth factor alpha (TGFα); Fibroblast growth factor 1 (FGF1); Platelet-derived growth factor receptor alpha (PDGFRα); and Vascular endothelial growth factor A (VEGFA).

RESULTS
In the group treated with betamethasone the number of neurons in the CA1; CA2; CA3; and dentate gyrus regions of hippocampus were significantly lower than control groups on postnatal day 1 and on postnatal day 2; which correspond to 22-24 and 24-28 gestational weeks in humans in terms of brain growth. However, the number of the neurons in the hippocampus was not significantly different between the groups on postnatal day 3; corresponding to 28-32 weeks in humans. All of the evaluated growth factors except PDGF and VEGFA showed up-regulation in steroid exposed groups. A linear relationship didn’t exist between neuronal count and growth factors response.

CONCLUSIONS
The present study demonstrates for the first time that steroid exposure during different stages of brain maturation showed differential effects on critical growth factors. Modulating effects of corticosteroids on growth factor response is depending on stage of brain development at the time of exposure and this may be one of the key determinants affecting the deleterious and beneficial effects of corticosteroids on central nervous system.

Poster 21

ASSOCIATION OF E-NOS GENE POLYMORPHISM IN DEVELOPMENT OF BRONCHOPULMONARY DYSPLASIA
Merih Çetinkaya; İpek Varıtak; Mary Korachi; Serin Guven; Ilke Mungan Akin; Cagdem Kaynar; Tuğba Erner Ercan; Gökhan Buyukkale; Sibel Selvik Orucmut
Kanuni Sultan Süleyman Training and Research Hospital

BACKGROUND
Nitric oxide is involved in multiple processes in the lung and all nitric oxide synthase (NOS) genes are expressed in airway epithelial cells. The aim of this study was to investigate possible association of eNOS gene polymorphism in development of BPD in premature infants.

PATIENT AND METHODS
This multi-center prospective study was performed in premature infants (≤ 32 weeks of gestation and/or ≤1500 g) who were admitted to the NICU with respiratory distress within the first 24 hours of life. Demographic and ventilation data of the infants were recorded. BPD was defined according to the National Institute of Child Health and Human Development/National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop definition. DNA isolation was carried out using the PureLinkTM Genomic DNA Mini Kit and the concentration of the DNA samples was measured by nanophotometerImplen P 300. For the SNP analysis of eNOS (rs1799983) optimized primers were used. Real Time Polymerase Chain Reaction(QRT-PCR) was carried out in a CFX96 thermocycler.

RESULTS
A total of 122 infants were enrolled and 55 of them developed BPD; whereas 67 did not have BPD. The mean gestational age and birth weight of these infants were significantly lower than those who did not develop BPD. The mean ventilation and supplemental oxygen duration were also significantly higher in infants with BPD compared with non-BPD group. None of infants without BPD had GG genotype.

CONCLUSIONS
This study shows for the first time that eNOS gene polymorphism is associated with development of BPD. GG ve TT genotypes of eNOS gene were found to be highly significant in infants with BPD.
DEVELOPMENT OF A NEW METHOD TO DETERMINE F2-ISOPROSTANES IN NEWBORN SERUM AND PLASMA SAMPLES

S. Andersson 1; C. Cháfer-Pericàs 1; J. Kuligowski 1; J. Escobar 1; A. Sánchez-Illana 1; I. Torres-Cuevas 1; V. Stefanovic 1; E. Cubells 1; M. Cernada 1; A. Núñez 1; M. Vento 1

1 Department of Obstetrics and Gynecology; FetoMaternal Medical Center; Helsinki University Hospital; Finland
2 Neonatal Research Centre; Health Research Institute La Fe; Valencia; Spain
3 Division of Neonatology; University & Polytechnic Hospital La Fe; Valencia; Spain

BACKGROUND

Isoprostanes (IsoPs) are stable products resulting of a non-enzymatic oxidation of polyunsaturated fatty acids. IsoPs derived from arachidonic acid (AA) peroxidation are called F2-isoprostanes. They are considered as the most reliable markers of oxidative stress in vivo [1]; which is linked to severe neonatal conditions such as bronchopulmonary dysplasia; retinopathy of prematurity; hypoxic/ischemic encephalopathy.

Reported cord plasma levels are between 0.07 and 0.12 nM/mL [2]. Moreover; total F2-isoprostanes are significantly higher for term (0.73 nM) and especially preterm (1.02 nM) newborn comparing with adults (0.52 nM) [3]. F2-isoprostanes can be determined in urine; serum and plasma samples of newborn. However; few validated methods to determine F2-isoprostanes in plasma and serum samples can be found in literature.

OBJECTIVE

The aim of this work was to validate a chromatographic-mass spectrometry method for the reliable determination of F2-isoprostanes within the limits of detection (LOD) that would be within levels usually found in healthy newborn plasma and serum samples.

Methods

Healthy term newborn infants’ cord blood was used for the determinations (n=10). The analytical method employed consisted of liquid chromatography coupled to mass spectrometry (LC-MS/MS). The analytes determined were F2-isoprostanes (8-iso-15(R)-PGF2α; 1a1b-dihomo-PGF2α; 2,3-dinor-iPF2α-III; 8-iso-15-keto-PGE2; 8-iso-PGE2; 5-iPF2α-VI; 2,3-dinor-iPF2α-III; 8-iso-15-keto-PGF2α; the PGs PGE2 and PGF2α). In addition to this; total parameters (isoprostanes; isofurans; neuroprostanes; neurofurans) were also determined.

RESULTS

The limits of detection (LOD) obtained for 8-iso-15(R)-PGF2α; 8-iso-PGF2α; PGF2α; 5-iPF2α-VI; 2,3-dinor-iPF2α-III and 8-iso-15-keto-PGF2α were satisfactory to determine these compounds in healthy adult human plasma or serum samples (range = 0.1-0.5 nM).

In the table we can see ranges of assessed concentrations in newborn serum samples. As regards total parameters; important differences were observed for neurofurans and especially isofurans among the serum samples analyzed.

Table. Limit of detection and assessed values of F2-isoprostanes by LC-MS/MS in healthy term newborn babies (n=10).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>LOD (nM)</th>
<th>Assessed concentrations (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8-iso-15(R)-PGF2α</td>
<td>0.5</td>
<td>0.5-32</td>
</tr>
<tr>
<td>8-iso-PGF2α</td>
<td>0.05</td>
<td>0.1-0.5</td>
</tr>
<tr>
<td>PGF2α</td>
<td>0.05</td>
<td>2.64</td>
</tr>
<tr>
<td>5-iPF2α-VI</td>
<td>0.05</td>
<td>1.67</td>
</tr>
<tr>
<td>2,3-dinor-iPF2α-III</td>
<td>0.2</td>
<td>0.4-2.3</td>
</tr>
<tr>
<td>8-iso-15-keto-PGF2α</td>
<td>0.3</td>
<td>0.3-200</td>
</tr>
</tbody>
</table>

CONCLUSIONS

The method developed provides satisfactory sensitivity and accuracy to carry out reliable determination of F2-isoprostanes and total parameters in newborn serum and plasma samples. In comparison to previous methods; this method has some advantages; such as; simple sample treatment and high selectivity to determine a lot of compounds in just one analysis. In addition to this; ranges of F2-isoprostanes concentrations in newborn serum samples have been established.
CONCLUSIONS
The wide clinical heterogeneity of pediatric diffuse lung diseases can be explained by the number of different genes involved and the variety of genetic mechanisms involved; including homozygosity; compound heterozygosity or; as suggested by these data; trans-heterozygosity. Targeted panel NGS appears to be a reliable method for mutation screening and complex phenotype identification; and should be integrated in combined genic and genomic strategies for comprehensive diagnosis and characterization of these rare diseases.

TARGETED NEXT GENERATION SEQUENCING FOR MUTATION DETECTION IN IDIOPATHIC NEONATAL AND PEDIATRIC DIFFUSE LUNG DISEASES
Olivier Danhaive; Donatella Peca; Renato Cutrera; Adriano Angioni
University of California San Francisco and Bambino Gesù Children’s Hospital; Rome

BACKGROUND
Next-Generation Sequencing (NGS) techniques allow fast; high-throughput mutation detection in cohorts of patients with heterogeneous genetic disorders. Unexplained acute and chronic diffuse lung disease in newborns and children are a heterogeneous group of rare diseases caused by genetic disorders of surfactant metabolism and by developmental vascular lung disorders such as alveolar capillary dysplasia; the molecular causes and mechanisms of which are still poorly understood.

OBJECTIVE
Our objectives were 1) to identify new and known disease-causing genetic variants in surfactant- or pulmonary vascular -related genes in a retrospective cohort of children 0-18 year-old with variable respiratory phenotypes ranging from neonatal hypoxic respiratory failure to chronic pulmonary hypertension or interstitial pneumonitis; and 2) to validate a targeted NGS panel using as a screening and diagnostic tool in these rare lung diseases.

METHODS
A custom-designed NGS panel including 9 surfactant-related genes (ABCA3; SFTPA1; SFTPA2; SFTPB; SFTPC; SFTPD; NKX2.1; CSF2Ra; CSF2Rb) and 15 developmental vascular genes (FOXF1; BMPR2; TBX4; MEOX2; TXNDC3; SMAD9; SMAD1; SMAD5; THBS1; ACVRL1; ENG; CBLN2; CRHBP; CRHR1; PPARδ) selected either by published data review or candidate gene approach; was applied in a subset of 17 cases aged 0-2 in a cohort of 127 cases referred from 2005 to 2014; 84 of which had been studied by Sanger exon sequencing in genes targeted for age of onset and clinical presentation. Copy number variation (CNV) analysis by array comprehensive genomic hybridization (aCGH) was performed in a subset of 8 cases.

RESULTS
Probable disease-causing genotypes were present in 24/84 cases (29%) analyzed by direct sequencing: ABCA3 (11 cases); SFTPC (8); NKX2.1 (2); FOXF1 (2) and TBX4 (1). In addition; single heterozygous mutations were present in ABCA3 (5 cases) and SFTPB (2 cases); of uncertain clinical significance since the related diseases are autosomal recessive. In the subset studied by NGS; 100% of the previously identified coding variants were confirmed; in addition; heterozygous coding variants were identified in other genes: CSF2Rb (4 cases); NKX2.1 (2); CRHR1 (1) and SMAD9 (1). Numerous non-coding variants of unknown significance were also present in all cases; aCGH revealed potentially disease-causing CNVs in 4 cases; involving TBX4 (1 case) and MEOX2 (1 case).
USEFUL INFORMATION

CONGRESS VENUE

AULA MEDICA
Karolinska Institute
Solnavägen 1, 171 77 Solna Sweden

CONGRESS MATERIAL

BADGES
Participants will receive their badges when collecting their Congress documents in the hotel lobby upon arrival. They are kindly requested to wear their badge at all time during the congress. Please note that admission to Scientific Session is restricted to participants wearing their badge.

CERTIFICATE OF ATTENDANCE
The Certificate of Attendance will be distributed at the end of the Congress.

CONTINUING MEDICAL EDUCATION ACCREDITATION
UEMS – European Union of Medical Specialists: 11 credits recognized.
The “30th International Workshop on Surfactant Replacement” has been accredited by the European Accreditation Council for Continuing Medical Educational (EACCME) for the entire congress. EACCME credits are recognized Europe-wide and in North America they can be exchanged for their national equivalent by contacting your national CME authority.

ORAL PRESENTATIONS
Speakers are kindly requested to hand their presentations to the organizers or the congress technicians the day before their presentation or at least 15 minutes before the beginning of the Scientific Programme.

POSTERS PRESENTATIONS
Poster Presenters are kindly requested to hang their posters at the beginning of the First day of the Congress (June 5th) and take them down at the end of the last day (June 6th). Poster numbers will be located on the poster panels.

OFFICIAL LANGUAGE
English is the official language of the Congress.

ORGANIZING SECRETARIAT
MCA Events srl
Via A. Binda, 34 | 20143 Milan, Italy
Tel: +39 02 34934404 | Fax: +39 02 34934397
www.mcascientificevents.eu | www.mca-group.eu

30th International Workshop on Surfactant Replacement has been organized with the unrestricted grant of Chiesi.
Also we would like to thank Ginevri for their collaboration.